Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Janku F, Beom SH, Moon YW, Kim TW, Shin YG, Yim DS, Kim GM, Kim HS, Kim SY, Cheong JH, Lee YW, Geiger B, Yoo S, Thurston A, Welsch D, Rudoltz MS, Rha SY. Janku F, et al. Among authors: kim tw, kim gm, kim sy, kim hs. Invest New Drugs. 2022 Oct;40(5):1001-1010. doi: 10.1007/s10637-022-01277-9. Epub 2022 Jul 8. Invest New Drugs. 2022. PMID: 35802288 Free PMC article. Clinical Trial.
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Lee KS, Yun T, Jeong SY, Choi HS, Lim SB, Chang HJ, Jung KH. Kim SY, et al. Among authors: kim tw, kim dy, kim jh. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):677-83. doi: 10.1016/j.ijrobp.2010.06.035. Epub 2010 Oct 1. Int J Radiat Oncol Biol Phys. 2011. PMID: 20888703 Clinical Trial.
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Kang MJ, et al. Among authors: kim tw, kim kp, kim sy, kim mj. Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25. Invest New Drugs. 2012. PMID: 21706149 Clinical Trial.
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ. Kim SY, et al. Among authors: kim tw, kim dy, kim jh. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):201-7. doi: 10.1016/j.ijrobp.2012.03.048. Epub 2012 Jun 5. Int J Radiat Oncol Biol Phys. 2013. PMID: 22672749 Clinical Trial.
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Hong YS, et al. Among authors: kim tw, kim kp, kim ty, kim sy, kim jh. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. Invest New Drugs. 2013. PMID: 22782485 Clinical Trial.
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Hong YS, Jung KH, Kim HJ, Kim KP, Kim SY, Lee JL, Shim BY, Zang DY, Kim JH, Ahn JB, Park YS, Kim TW. Hong YS, et al. Among authors: kim hj, kim tw, kim kp, kim sy, kim jh. Am J Clin Oncol. 2013 Dec;36(6):565-71. doi: 10.1097/COC.0b013e31825d52d5. Am J Clin Oncol. 2013. PMID: 22868243 Clinical Trial.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. Hong YS, et al. Among authors: kim tw, kim kp, kim sy, kim jh. Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10. Lancet Oncol. 2012. PMID: 23062232 Clinical Trial.
12,527 results
You have reached the last available page of results. Please see the User Guide for more information.